# A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

> **NCT01594970** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 800 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** Bimatoprost 0.01%

## Key facts

- **NCT ID:** NCT01594970
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2014-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01594970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01594970, "A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01594970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*